



## **Annex I: Summary of Product Characteristics for Angiotensin II Receptor Antagonists (AIIRAs)**

### Section 4.3 Contraindication

Second and third trimesters of pregnancy (see sections 4.4 and 4.6).

*[Contraindication for lactation to be deleted, if applicable]*

### Section 4.4 Special warnings and precautions for use

*Pregnancy:* AIIRAs should not be initiated during pregnancy. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).

### Section 4.6 Pregnancy and lactation

*Pregnancy:*

The use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4). The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 and 4.4).

Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor Inhibitors (AIIRAs), similar risks may exist for this class of drugs. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately and, if appropriate, alternative therapy should be started.

Exposure to AIIRA therapy during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3.)

Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.

Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3 and 4.4).

*Lactation:*

Because no information is available regarding the use of [Product] during breastfeeding, [Product] is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.

## **Annex II Package Leaflet for Angiotensin II Receptor Inhibitors**

### **Before you take [Product]**

#### ***Do not take [Product]***

*If you are more than 3 months pregnant. (It is also better to avoid [Product] in early pregnancy – see pregnancy section.)*

[Contraindication for lactation to be deleted, if applicable]

#### ***Take special care with [Product]***

*You must tell your doctor if you think you are (or might become) pregnant. [Product] is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).*

### ***Pregnancy and breast feeding***

#### ***Pregnancy***

*You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking [Product] before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of [Product]. [Product] is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.*

#### ***Breastfeeding***

*Tell your doctor if you are breast-feeding or about to start breast-feeding. [Product] is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.*